tbuckley/cabot-search huggingface dataset:
TCT-560 In-stent restenosis assessed by optical coherence tomography (OCT) indicates smooth coronary arterial healing process in second generation drug eluting stents (DES)
Authors: Takashi Kajiya, Junichiro Takaoka, Kengo Fukunaga, Ryoichi Arima, Akihiro Miyamura, Nobuhiko Atsuchi, Hiroshi Yamaguchi, Yoshihiko Atsuchi
Journal: Journal of the American College of Cardiology (2015)
GW26-e4547 Effects of Ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation
Authors: Yaodong Li, Yutong Ji, Xianhui Zhou, Jinxin Li, Qiang Xing, Yifan Hong, Baopeng Tang, Baoepng Tang
Journal: Journal of the American College of Cardiology (2015)
Fertility outcomes in young women with breast cancer: A Web-based survey
Authors: A. H. Partridge, S. Gelber, J. Peppercorn, E. Sampson, M. Laufer, R. Rosenberg, M. Przypyszny, A. Rein, E. P. Winer
Journal: Journal of Clinical Oncology (2004)

6085 Background: Many young women with breast cancer are interested in preserving fertility. We evaluated fertility outcomes of breast cancer survivors with the Young Survival Coalition (YSC), an advocacy group for young women with breast cancer. Methods: We developed a survey about fertility issues for women with early breast cancer. A link to the survey was emailed to all registered YSC survivor members (N= 1702). Eligible members were asked to complete the survey. Email reminders were used. Results: 657 women completed the survey. Mean age at breast cancer diagnosis was 32.9 years; mean current age 35.8 years. 90% of women were white; 62% married, 23% never married; 76% college graduates. 93% were having regular monthly periods at diagnosis. Stages included: 0 (10%), I (27%), II (47%), III (13%). Only 24% of women reported that, at diagnosis, they did not want a future pregnancy. 12% of women took steps to preserve fertility through treatment. 86% received chemotherapy, 43% tamoxifen, 3% aromatase inhibitor, and 14% ovarian suppression; 9% received no systemic treatment. At a median follow-up of 1.8 years, 8% reported recurrent disease. 78% of women overall, including 78% of the women who received chemotherapy, were still menstruating. 12% of women had been pregnant at least once, with 2% reporting spontaneous abortions and 2% therapeutic abortions; 7% had at least one live birth. Only 18% of women who wanted a future pregnancy at diagnosis had become pregnant. 10% reported having tried to become pregnant since diagnosis and 58% of these women reported at least one pregnancy. In a multivariate model, pregnancy after breast cancer was associated with younger age at diagnosis (age <30 vs. age 30–35, O.R. 0.76, p = 0.37; age <30 vs. age >35, O.R. 0.30, p=0.002), longer time since diagnosis (per year O.R 1.21, p <0.0001) and no tamoxifen treatment (O.R. 3.49, p <0.0001). Nonsignificant covariates included stage, fear of recurrence, chemotherapy, and prior fertility history. Conclusions: Most young women continue to menstruate following treatment for breast cancer, including chemotherapy. A relatively small percentage of women in this series have become pregnant, however the median follow-up is short. No significant financial relationships to disclose.
TCT-246 Impact of thrombus age on efficacy of manual thrombus aspiration: subanalysis form the PATA STEMI trial
Authors: Dejan Orlic, Jelena Kostic, Milica Labudovic Borovic, Milorad Tesic, Dejan Milasinovic, Branko Beleslin, Sinisa Stojkovic, Goran Stankovic, Miodrag C. Ostojic
Journal: Journal of the American College of Cardiology (2015)
GW27-e0232 A Double-blind, Randomized Controlled Trial of Genotype-based Warfarin Initiation in Patients with Mechanical Heart Valves
Authors: Xu Zhe, Shu-Yu Zhang, Rong Hu, Zhi-Ping Wang, Jing-Song Ou, Sheng-Li Yin, Jia-Li Li, Min Huang, Xi Zhang
Journal: Journal of the American College of Cardiology (2016)
Metastatic breast cancer and circulating exosomes. Hints from an exploratory analysis
Authors: L. Gerratana, B. Toffoletto, M. Bulfoni, D. Cesselli, A.P. Beltrami, C. Di Loreto, M. Bonotto, M. Cinausero, M. Isola, S. Marzinotto, A.M. Minisini, R. Sottile, M. Mansutti, G. Fasola, F. Puglisi
Journal: Annals of Oncology (2015)
Introduction to the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks — United States
Authors: Ralph J. Coates, Martha Stanbury, Ruth Jajosky, Kimberly Thomas, Michele Monti, Patricia Schleiff, Simple D. Singh
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

With this 2016 Summary of Notifiable Noninfectious Conditions and Disease Outbreaks - United States, CDC is publishing official statistics for the occurrence of nationally notifiable noninfectious conditions and disease outbreaks for the second time in the same volume of MMWR as the annual Summary of Notifiable Infectious Diseases and Conditions (1). As was the case for the 2015 Summary of Notifiable Noninfectious Conditions and Disease Outbreaks (2), this joint publication is the result of a request by the Council of State and Territorial Epidemiologists (CSTE) to provide readers with information on all nationally notifiable conditions and disease outbreaks in a single publication.
Tertiary Center Referral Patterns for Myelodysplastic Syndrome (MDS) Patients Are Suggestive of Age and Race Disparities
Authors: Dan P. Zandberg, Jason Bierenbaum, Ivana Gojo, Michael L. Tidwell, Yi Ning, Xianfeng Frank Zhao, Amy J. Davidoff, Maria R. Baer
Journal: Blood (2010)
TCT-480 National Trend in Multivessel Percutaneous Coronary Intervention in Patients with Diabetes Mellitus in the United States
Authors: Ashraf AbuSara, Shimin Zheng, Yan Cao, Hemang B. Panchal, Samit Bhatheja, Eunice Mogusu, Kais Albalbissi, Timir K. Paul
Journal: Journal of the American College of Cardiology (2015)
Differences in immunohistochemical features between invasive breast cancers and DCIS lesions from a single population, based on a consecutive case series of 1,248 patients.
Authors: Sven Kurbel, Branko Dmitrovic, Ksenija Marjanovic
Journal: Journal of Clinical Oncology (2014)

e22084 Background: If all breast cancer types evolve from DCIS lesions, speed of tissue invasion can be calculated from breast tumor type distributions among DCIS lesions and among invasive cancers (Tumour Biol 2013;34:1-7.). Methods: Histologic data of 68 DCIS and 1,180 invasive ductal cancer (IDC) patients were collected and analyzed. Results: ER+PgR- phenotype was more common in Luminal B2 than among the pooled Luminal A&B1 (p=0.0002), more in Luminal B1 than in Luminal A (p=0.0167). The same phenotype was associated with age older than 54 in Luminal B1 and in B2 patients. HER2 type cancers were more often in older patients (p=0.0038). Tumor progression from DCIS to IDC was found 39% faster than the average in Luminal B1 tumors, supporting the clinical importance of this tumor type. The rare combination of low Ki-67 in HER2 type cancers (only 14% of HER2 type cancers) showed very slow transition to IDC (only 53.55% of the average speed), while the triple negative cancers were faster than the average, almost despite the Ki-67 value (104.63% for the low and 114.27% for the high Ki-67 tumors). In three tumor types with positive steroid receptors the ER+PgR- phenotype showed slower IDC transition than the ER+PgR+ phenotype of the same tumor type (speed difference of 38% for Luminal A, 46% for Luminal B1 and 67% for Luminal B2 with Ki67>14%). Triple-negative tumors in younger patients were 24% faster than the expected average, while in HER2 type tumors, in younger patients the tissue invasion speed was 20% below the expected values. Conclusions: The relative tissue invasion speed differed substantialy among our patients. Differences depended on tumor types, steroid expression phenotypes and age. It seemed that in ER+PgR- tumors, if ligand binding to ERs does not promote PgR expression, it also does not stimulate the tissue invasion. In triple negative tumors, an age dependent premenopausal mechanism seems possible as an accelerator of tissue invasion, while the invasion of HER2 overexpressed tumors in older patients possibly depended on an unidentified mechanism that takes more time to be acquired, so it was less present in premenopausal patients.
Cyclin D1 (CD1), interleukin-6 (IL-6), Ki67, transforming growth factor beta type II receptor, HER-2 and prediction of relapse in women with early stage breast cancer (BC) taking tamoxifen
Authors: H. B. Muss, J. Y. Bunn, A. M. Crocker, B. Beatty, M. J. Donovan, P. A. Kaufman, K. Plaut, M. Rincon, D. Verbel, D. L. Weaver
Journal: Journal of Clinical Oncology (2004)

9523 Background: Determining which women with early stage, receptor positive BC will respond to tamoxifen therapy would be of great importance to patients and clinicians. Methods: A total of 126 patients were identified and included in our analysis; all patients had Stage I-IIIa (AJCC v5), ER and/or PR positive BC and were treated with adjuvant tamoxifen therapy. Clinical data were obtained from a medical chart review and biomarkers were measured using immunohistochemistry (IHC) on paraffin-embedded archival tissue. HER-2 and CD1 were also measured using fluorescent in situ hybridization (FISH) to detect gene amplification. All data were analyzed using univariate as well as multiple logistic regression methods. Also, support vector machines (SVM), a supervised learning approach, were used to develop a model that included all clinical and biomarker combinations to predict recurrence in the 126 patients described above. The SVM model was tested in 18 similar patients. Results: In a multivariate analysis which included age, tumor size, number of positive nodes, tumor grade, time on tamoxifen, and the described biomarkers, neither radiation therapy, chemotherapy, nor any biomarkers were significantly predictive of relapse. When CD1 or IL-6 were added to the model individually both demonstrated significance in predicting tamoxifen response (p=0.031, p=0.045, respectively). When both CD1 and IL-6 were added to the model, neither was significant, likely a result of the high correlation of the two markers. Using the SVM approach, clinical and biomarker data combined correctly predicted relapse on tamoxifen in 78.6% of the 126 women in the training set and in 77.8% of the 18 women in the test set. Conclusions: When added to standard clinical variables, either increased CD1 or decreased IL-6, but not HER-2, significantly predicted increased relapses on tamoxifen. In addition, using all of these markers in an SVM analysis, tamoxifen-failure was correctly predicted in nearly 80% of the women. Support: Breast Cancer Research Foundation, New York, NY; Aureon Biosciences, Yonkers, NY. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aureon Biosciences Aureon Biosciences Aureon Biosciences Breast Cancer Research Foundation (NY); Aureon
Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Chemotherapy-Sensitive, Relapsed/Refractory (CSRR) Human Immunodeficiency Virus (HIV)-Associated Lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) Trial
Authors: J Alvarnas, J Le Rademacher, Y Wang, Richard F. Little, G Akpek, E Ayala, S Devine, L Kaplan, A Noy, U Popat, J Thompson, M H Horowitz, A Mendizabal, W H. Navarro, R Ambinder
Journal: Blood (2014)
Long-term effect of Wnt/β-catenin small molecule inhibitor CWP232291 on intestinal carcinogenesis in novel GEM model deficient in Smad4 and p53.
Authors: Jun Won Park, Jung Min Park, Jeffrey E. Green, Hark K. Kim
Journal: Journal of Clinical Oncology (2016)

594 Background: We have established and characterized a novel genetically-engineered mouse (GEM) model for colorectal cancer by performing intestinal epithelium-specific knockout of Smad4 and p53 under Villin promoter. CWP232291 (JW Pharmaceutical Corporation, Seoul, Korea) is a potent Wnt/ β-catenin small molecule inhibitor currently tested in several Phase I trials. We evaluated chemopreventive efficacy of long-term CWP232291 treatment for intestinal carcinogenesis in our novel GEM model. Methods: Three-week-old GEM mice were intraperitoneally injected BIW for 17 weeks with 100 mg/kg CWP232291 (n = 19) or vehicle normal saline (n = 27) and then sacrificed. Results: All Villin-Cre;Smad4 F/F ;Trp53 F/F mice developed multiple spontaneous intestinal tumors with the high proliferative activity and the activation of Wnt signaling pathway (median adenocarcinoma-free survival, 5.4 months; incidence of adenocarcinoma, 75.9 %). Whereas, Villin-Cre;Smad4 F/F or Villin-Cre;Trp53 F/F micedidn’t develop any intestinal tumors until 20 weeks. A histological assessment showed that tumor-bearing mice were significantly reduced after CWP232291 treatment (CWP232291, 50.0% vs vehicle, 84.0%; P &lt; 0.01). More importantly, CWP232291 showed significant decrease in the incidence of malignant tumors (CWP232291, 37.5% vs vehicle, 78.3%; P &lt; 0.05). In addition, tumor multiplicity is significantly decreased in CWP232291-treated mice (CWP232291, 1.2 ± 0.4 vs vehicle, 2.8 ± 0.4, P &lt; 0.01). Immunohistochemistry showed that CWP232291 treatment reduced β-catenin, myc and cyclin D1 levels in tumors. In-vivo limiting dilution assay using primary mouse cancer cells showed that the frequency of cancer stem cells (CSCs) was 1/3,223 for the untreated group and 1/48,069 for the CWP291-treated group (p &lt; 0.001). Conclusions: These results showed that CWP232291 inhibited Wnt signaling and reduced the CSCs through down-regulation of β-catenin and Wnt target genes and exerted a chemopreventive effect in our GEM model. This suggests that CWP232291 may be a promising candidate for colorecal cancer chemoprevention and maintenance.
TCT-715 Transcatheter valve-in-valve and valve-in-ring implantation for degenerated mitral valve bioprostheses or failing surgical rings
Authors: Christian Frerker, Tobias Schmidt, Ralf Bader, Dimitry Schewel, Michael Schlüter, Thomas Thielsen, Jury Schewel, Felix Kreidel, Hannes Alessandrini, Friederike Schlingloff, Ulrich Schäfer, Karl-Heinz Kuck
Journal: Journal of the American College of Cardiology (2015)
Rituximab for the Treatment of Isolated Refractory Desquamative Gingivitis Due to Mucous Membrane Pemphigoid
Authors: Stefanie Haefliger, Michael P. Horn, Valerie G. A. Suter, Michael M. Bornstein, Luca Borradori
Journal: JAMA Dermatology (2016)

loid deposition.This unique case highlights that cutaneous signs of amyloidosis can resolve after treatment, and may suggest that systemic deposition of amyloidosis is, to a certain degree, reversible as well.Cutaneous lesions of systemic amyloidosis are demonstrated in approximately 20% to 40% of patients. 1Characteristic lesions include waxy papules, "pinch purpura" of the periorbital area, macroglossia, and hemorrhagic bullae.Ecchymoses and purpura are caused by amyloid infiltration in the blood vessels making the skin susceptible to trauma.The presentation of milia on the hands is a recently recognized manifestation of amyloidosis; minor trauma is implicated in the formation of these lesions. 1 Nail findings of amyloidosis were first confirmed in 1979 by a longitudinal nail biopsy and may mimic lichen planus and graft-vs-host disease. 2,3 In a review of 20 cases of systemic amyloidosis, five patients had nail dystrophy as the sole cutaneous indicator of systemic amyloidosis. 3Amyloid infiltration of the nail matrix is thought to be the cause of brittleness, longitudinal ridging and crumbling; patients may complain of having soft or thin nails. [1]][3][4] Characteristic findings on the scalp can further serve as a clue of underlying disease.Infiltration of hair follicles by amyloid protein results in diffuse nonscarring alopecia. 5Amyloid deposition is appreciated in a perifollicular distribution in scalp biopsies and is hypothesized to cause vascular impairment, resulting in inhibition of anagen reconstitution. 6 The affected hair demonstrates thinning, broken hairs, black dots, and salmon-colored halos surrounding the follicular ostia. 5 In summary, the cutaneous manifestations of systemic amyloidosis can present with nail and skin findings, and should be recognized timely for the most efficacious management.As demonstrated in this case, nail changes are not only diagnostic of the disease and may mimic lichen planus clinically, but can serve as an indicator for treatment response.Future research should be explored to see if cutaneous resolution helps predict regression of systemic amyloidosis and a more favorable prognosis in patients with underlying plasma cell dyscrasias.
TCT-726 Incidence, Characteristics, and Clinical Course of Left Atrial Thrombus Attached to Watchman Device in Atrial Fibrillation Patients
Authors: Shunsuke Kubo, Yukiko Mizutani, Emily Tat, Asma Hussaini, Takahiro Shiota, Robert Siegel, Saibal Kar
Journal: Journal of the American College of Cardiology (2015)
TCT-640 Clinically silent pseudoaneurysms after transcatheter aortic valve implantation (TAVI) using the ProStar XL system-comparison between the CoreValve, the Edwards Sapien XT and the Edwards Sapien 3 Valve
Authors: Suzanne Fateh-Moghadam, Rezo Jorbenadze, Antonios Kilias, Michael Droppa, Patrik Htun, Meinrad Gawaz, Wolfgang Bocksch
Journal: Journal of the American College of Cardiology (2015)
Patient involvement in French Lung cancer guidelines: A qualitative study
Authors: A. Bataillard, J. Carretier, H. Cazeneuve, B. Fervers
Journal: Journal of Clinical Oncology (2008)

7603 Background: Clinical Practice Guidelines (CPGs) are increasingly used and regarded as mandatory references for clinical decisions and patient centered cancer care. Discrepancies between recommendations and patient’s preferences have been found to be an important factor of non-compliance with CPGs. To improve the quality and efficiency of cancer CPGs, the French Standards, Options and Recommendations (SOR) program has adapted methods validated in other settings to involve patients in the development of guidelines. Objective: To assess barriers and facilitators of involving patients in the Guideline Development Group (GDG) for a CPG on treatment of early-stage non-small cell lung cancer (NSCLC). Methods: Qualitative study (January 2006 to March 2007) combining 8 direct observations of GDG meetings and 12 semi-directive interviews with the participating patients and experts. Results: The barriers and facilitators indentified could be grouped into four categories (see table). Conclusion: Our observations concerning patient involvement in CPGs were similar to those made in other contexts and permitted to clarify some of the parameters that govern patient involvement in French CPG development. Barriers and facilitators Dimensions Facilitators Barriers Topic of CPG - Patient’s feeling of shame linked with NSCLC - Poor prognosis - Technicity of the topic Method of patient involvement - Recruitment means - Gap between the role of expert assigned to patients and their capability to participate - Training - Support - Time for appropriation - Small numbers of patients Patients’ characteristics - Availability Lack of concern and interest - Strong concern and interest for the topic Interactions within the GDG - Mentioning professional experience Technical analysis and discussion of the scientific data - Listening and explanation by experts - Sense of belonging No significant financial relationships to disclose.
TCT-310 Peripheral pressure wire measurement of the below-the knee arteries in critical limb ischemia: validation with angiography and Laser Doppler measurements
Authors: None zoltán ruzsa, Szilárd Róna, Balazs Nemes, Balazs Berta, Kalman Huttl, Béla Merkely
Journal: Journal of the American College of Cardiology (2015)
Expression Profiling of ABC Transporter Genes in Chronic Myeloid Leukemia (CML) and Responsiveness to Imatinib
Authors: Nunzio Iraci, Simona Soverini, Samuele Gherardi, Emanuele Valli, Fausto Castagnetti, Roberto Bernardoni, Gianantonio Rosti, Giuliano Della Valle, Francesca Palandri, Gabriele Gugliotta, Fabrizio Pane, Giuseppe Saglio, Nicola Esposito, Daniela Cilloni, Fabrizio Quarantelli, Enrico Gottardi, Michele Baccarani, Giovanni Martinelli, Giovanni Perini
Journal: Blood (2008)
GW27-e0703 The effect of Candesartan on TLR7 expression and downstream inflammation in THP-1 macrophages and its mechanism
Authors: Huang Weijun, Gaifeng Hu, Huiyu Tong, Meijun Li, Linlin Mai, Dezhu Chen, Jiaqi Tan, Yingwen Chen, Yuli Huang, Yunzhao Hu
Journal: Journal of the American College of Cardiology (2016)
Enterococcal Metabolite Cues Facilitate Interspecies Niche Modulation and Polymicrobial Infection
Authors: Damien Keogh, Wei Hong Tay, Yao Yong Ho, Jennifer L. Dale, Siyi Chen, Shivshankar Umashankar, Rohan B.H. Williams, Swaine L. Chen, Gary M. Dunny, Kimberly A. Kline
Journal: Cell Host & Microbe (2016)
Phase I Dose Esclation of Activated T Cells (ATC) Armed with Anti-CD3 × Anti-CD20 Bispecific Antibody (CD20Bi) after Stem Cell Transplant (SCT) In Non-Hodgkin's Lymphoma (NHL)
Authors: Lawrence G. Lum, Voravit Ratanatharathorn, Archana Thakur, Zaid Al-Kadhimi, Cassara Skuba, Elyse N. Paul, Patricia A. Steele, Lois Ayash, Muneer H. Abidi, Joseph P. Uberti
Journal: Blood (2010)
Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma.
Authors: Stefan Peinert, Rosemary Hoyt, Jeffrey Szer, John F. Seymour, H. Miles Prince, Andrew W Roberts, Luigi Rigacci, Andrew Grigg, David S. Ritchie
Journal: Blood (2008)
Pazopanib for the treatment of metastatic nonadipocytic soft-tissue sarcoma.
Authors: Fazil Aydin, Turkan Ozturk Topcu, Feyyaz Ozdemir, nazim Onur Sahin, Halil Kavgaci, Mustafa Kandaz
Journal: Journal of Clinical Oncology (2014)

e21513 Background: Pazopanib is a multikinase inhibitor drug for treatment of metastatic non-adipocytic soft tissue sarcomas (STS) of chemotherapy inefficacy. Pazopanib is an orally-administered potent small molecule inhibitor of all VEGF receptor subtypes. Therefore, its actions are expected to be primarily anti-angiogenic. We present our clinical experience to evaluate the safety and efficacy in routine clinical practice. Methods: Fourteen patient were treated in our clinic between October 2012 and December 2013. Response was evaluated according to RECIST 1.1 criteria and treatment toxicity assessed. Results: Fourteen patients were assessed, four male, ten female patients. Patients had a median age of 53.4 years (range 23-81). Primary sites were limb (7.1%), abdominal cavity (71.1%) and trunk (21.4%). Median number of previous chemotherapy lines was 2 and all patients were angiogenesis inhibitor naive. Dose reduction was performed only for one patient due to liver toxicity. The most common side effects included fatigue (35.7%), liver function abnormalities (21.4%) diarrhoea (14.3%), anemia (14.3%) pulmonary emboli (14.3%).There were a partial response patient with metastatic undifferentiated pleomorphic sarcoma in abdominal cavitation(7.1%). There were 9 stable disease (64.3%) 4 progressive disease (28.6%). Clinical benefit rate (PR+SD) was 71.4%. At a median follow-up of 18.2 weeks (range: 4.3-60.7), 9 patients (64.3%) were still alive and 8 (88.8%) were progression free. Median TTP was 29.8 weeks (range 10-56). Conclusions: Despite pazopanib is a new treatment option for patients with soft tissue sarcomas, pazopanib should be considered as part of the standard treatment because of efficiacy and manageable side effect profile.
GW27-e0874 The impact of prior use of four preventive medications on outcomes in patients hospitalized for acute coronary syndrome--Results from CPACS-2 Study
Authors: Min Li, Yubei Huang, Xin Du, Shenshen Li, Anushka Patel, Runlin Gao, Jiachao Ji, Yangfeng Wu
Journal: Journal of the American College of Cardiology (2016)
TCT-781 Thoracic Endovascular Repair Decreases Longitudinal Aortic Distensibility: Experimental Study in an Ex-Vivo Porcine Model
Authors: Foeke J. Nauta, Michele Conti, Stefania Marconi, Arnoud V. Kamman, Gianluca Alaimo, Simone Morganti, Anna Ferrara, Joost van Herwaarden, Frans L. Moll, Ferdinando Auricchio, Santi Trimarchi
Journal: Journal of the American College of Cardiology (2015)